One patent currently held, every record listed here
4 more in force are now held by other companies
Held is read from USPTO's recorded assignments; a transfer never recorded there does not appear.
The next term ends in Jun 2027. from the record
Of the 4 now held by other companies, 2 name Sapphiros Laboratories LLC as their current owner, and 2 more name another party. Each row says which.
Free plan: 3 watched companies. Pro: unlimited.
Alerts on its grants, lapses and transfers.
1
Ending by 2030
Jun 2027
Next term end
1
Patent families
When these terms end
Each bar runs from grant to computed term end. 2012 to 2037.
US 8,105,775
IL-1 Gene Cluster and Associated Inflammatory Polymorphisms and Haplotypes
Jun 25, 2027
US 8,101,360
IL-1 Gene Cluster, Insulin Resistance and Coronary Artery Disease Associated Polymorphisms and Haplotypes and Methods of Using Same
Jun 3, 2029
US 9,347,090
Method for Determining Severity and Progression of Periodontal Disease
no later than Apr 19, 2032
20172022202720322037
A dotted end marks a recorded terminal disclaimer this site has not resolved: the term can only be shorter than the bar, never longer.
Every computed term in this portfolio is shown above.Updated Nov 15, 2026 · includes USPTO assignment & status data published Nov 15, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
Notable patents
Ranked by citations and family size, against patents of the same kind granted the same year. How we rank
Only 1 of the currently held patents qualifies as notable.
Formerly held, still cited
Notable
Ends no later than Apr 2032 · Medium confidence
Granted 2016 and renewed at every maintenance window due so far. Protection runs to 2032. A terminal disclaimer is on file and its reference is not resolved, so no cap is applied and the date may move earlier, never later.
now held by Sapphiros Laboratories LLC
Also notable
Ends Jul 2037 · High confidence
The newest of the three, granted 2019. It anchors the portfolio to 2037, later than anything else here. A terminal disclaimer caps this term to an earlier patent's.
now held by Sitokine Limited
Fee deadlines
No maintenance fee falls due on this company's record before Nov 10, 2027.
Recent changes
Nothing was recorded against this company's patents in the last 90 days.
What they patent
Grouped by real patent family, largest first, labeled by the earliest filing in each. No technology classification is inferred from titles.
| IL-1 Gene Cluster and Associated Inflammatory Polymorphisms and Haplotypes | 1 in force | to Jun 2027 |
Patents held now
Soonest term end first.
Showing 1 to 1 of 1
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,105,775 | IL-1 Gene Cluster and Associated Inflammatory Polymorphisms and Haplotypes In force · High confidence | In force | High confidence |
Also on record, not counted in the 1: 4 patents in force now held by others · 5 patents ended · 29 applications abandoned. List them
Sources and methods
Compiled from USPTO application file histories, grants and recorded assignments, with the company's own names reviewed by hand. How this record was built
Portfolio grouped automatically from ownership conveyances to the names matched to this company, usually every name that begins with its own, so it counts patents an affiliate holds; each list row names the holder of record. Security interests are excluded and ambiguous records are not reviewed by hand.
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
2 terminal disclaimers are on file with no resolved reference. No cap is applied and none is guessed
3 computed term dates come from a chain with an unresolved parent. A continuity parent has not yet been fetched from USPTO's records. The term is dated from this application's own claim; no earlier date is assumed until the parent is resolved.